Long-term control of congestive heart failure with captopril. 1982

F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo

The long-term effects of captopril therapy were assessed by sequential hemodynamic studies over a 6 month period in 19 patients with resistant congestive heart failure. Initial improvement during the first week of therapy was noted only in 11 and was marked by significant (p less than 0.005) increases in cardiac output and stroke volume, slowing of heart rate, and reduction of total peripheral resistance. Of the remaining eight patients, seven improved subsequently with maintained therapy so that by the end of 3 months of treatment only one patient failed to respond significantly. The hemodynamic index that reflected response most consistently was the shortening in pulmonary mean transit time. Simultaneously with clinical improvement there was a reduction in cardiopulmonary volume that reflected a reduction in pulmonary congestion and probably systemic vasodilation. Associated with these hemodynamic changes there was an increase in plasma renin activity and a significant reduction in plasma aldosterone, but these changes did not differ significantly between patients who responded markedly and those who responded moderately to converting enzyme inhibition. These results suggest that the response of congestive heart failure to captopril can occur gradually. Improvement was related to peripheral hemodynamic changes which led to a reduction in both total peripheral resistance and cardiopulmonary volume. The reduction in the plasma aldosterone/renin activity ratio was an effective marker of compliance.

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001810 Blood Volume Volume of circulating BLOOD. It is the sum of the PLASMA VOLUME and ERYTHROCYTE VOLUME. Blood Volumes,Volume, Blood,Volumes, Blood
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine

Related Publications

F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
April 1990, Zhonghua xin xue guan bing za zhi,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
January 1982, British journal of clinical pharmacology,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
June 1986, The Journal of the Association of Physicians of India,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
May 1984, The American journal of cardiology,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
January 1982, British journal of clinical pharmacology,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
September 1983, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
January 1986, Ceskoslovenska fysiologie,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
January 1984, Zhonghua nei ke za zhi,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
May 1984, Harefuah,
F M Fouad, and R C Tarazi, and E L Bravo, and N J Hart, and L W Castle, and E E Salcedo
July 1990, Indian pediatrics,
Copied contents to your clipboard!